High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer

Chia Lun Chang, Kevin Sheng Po Yuan, Szu Yuan Wu

研究成果: 雜誌貢獻文章同行評審

14 引文 斯高帕斯(Scopus)

摘要

Background: No randomized studies have compared low-dose or high-dose concurrent chemoradiotherapy (CRT). Methods: In this study, 7219 patients with stage III or IV head and neck squamous cell carcinoma (HNSCC) were enrolled and categorized into 2 groups: group 1, comprising those undergoing low-dose concurrent CRT (n = 1575), and group 2, comprising those receiving high-dose concurrent CRT (n = 5644). Results: Cox regression analyses revealed that age ≥65 years, male, high Charlson comorbidity index (CCI) scores, radiotherapy (RT) duration ≥7.5 weeks, clinical stage IV cancer, oral cavity cancers, tobacco smoking, and total cisplatin dose ≥240 mg/m2 were significant independent prognostic risk factors for overall survival (OS). After adjustment for confounders, the adjusted hazard ratio (aHR; 95% confidence interval [CI]) for overall mortality was 0.83 (0.78-0.89; P < .001) in patients with oral cavity HNSCC undergoing high-dose concurrent CRT and 0.82 (0.77-0.94; P < .001) in patients with nonoral cavity HNSCC receiving high-dose concurrent CRT. Conclusion: High-dose concurrent CRT can reduce the incidence of death in patients with stage III or IV HNSCC.
原文英語
期刊Head and Neck
DOIs
出版狀態接受/付印 - 2017

ASJC Scopus subject areas

  • Otorhinolaryngology

指紋 深入研究「High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer」主題。共同形成了獨特的指紋。

引用此